### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

O	MB APPR	ROVAL
OMB Num	nber:	3235-0287
Estimated	average	
hours per	response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)												
1. Name and Address of Reporting Person*  COOPER ROBIN D G  (Last) (First) (Middle)  RIGEL PHARAMCEUTICALS, INC.,, 1180  VETERANS BLVD.  (Street)  SOUTH SAN FRANCISCO, CA 94080			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]      3. Date of Earliest Transaction (Month/Day/Year)     01/20/2005					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below) Other (specify below)  Sr. V.P. Pharmaceutical Scs.  6. Individual or Joint/Group Filing/Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
							X					7)		
			4. If Amendment, Date Original Filed(Month/Day/Year)									_X_ Fo		
(Cir		(State)	(Zip)			Tabl	le I - Non-Deriv	ative Securities	Acquired, 1	Disposed (	of, or Benef	icially Owned		
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date r) any (Month/Day/Ye		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Owned Following Reported Transaction(s)		neficially 6	6. 7. N Ownership Form: Ben	7. Nature of Indirect Beneficial Ownership		
				(World)	/Day/Tear)		Code V An	(A) or (D)	Price				(Instr. 4)	
							in this fo	rm are not re	quirea to re	espona u	niess the	ıorın dispiay	S	
1. Title of Derivative Security (Instr. 3)		*****	3A. Deemed Execution Date, if	(e.g., pu 4. Transacti Code	5. Num on Of Derivat Securit	arran ber tive ies		tly valid OMB ed of, or Benefi vertible securit ble and	control nu	Amount	8. Price of	9. Number of Derivative Securities Beneficially Owned	10. Ownersh Form of Derivativ	Beneficia Ownershi
Derivative Security	Conversion or Exercise Price of	Date	3A. Deemed Execution Date, if any	(e.g., pu 4. Transacti Code	5. Num of Derivat	arran iber iive ies ed	a current cquired, Dispos nts, options, con 6. Date Exercisa Expiration Date	tly valid OMB ed of, or Benefi vertible securit ble and	control nu icially Owne ies)  7. Title and of Underlyi Securities	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially	10. Ownersh Form of Derivativ Security: Direct (I or Indire	of Indirect Beneficia Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	(e.g., pu 4. Transacti Code (Instr. 8)	sts, calls, w 5. Num on of Derivat Securit Acquire (A) or Dispose of (D) (Instr. 3	arran iber iive ies ed ed	a current cquired, Dispos nts, options, con 6. Date Exercisa Expiration Date	tly valid OMB ed of, or Benefi vertible securit ble and	control nu icially Owne ies)  7. Title and of Underlyi Securities	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownersh Form of Derivativ Security: Direct (I or Indire ) (I)	of Indirect Beneficia Ownershi (Instr. 4)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
COOPER ROBIN D G RIGEL PHARAMCEUTICALS, INC., 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			Sr. V.P. Pharmaceutical Scs.			

## **Signatures**

James H. Welch (Attorney-in-Fact)	02/01/2005
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Vests monthly over one year from 1/01/05.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \textit{see} \ Instruction 6 for procedure.$ 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.